While the reduction in price target from $40 to $31 could suggest a tempered outlook on ACADIA Pharmaceuticals' short-term price potential, the maintenance of an Outperform rating by Baird indicates a continued positive view on the company's longer-term prospects. This mixed signal could lead to neutral short-term price movement as investors weigh the lowered price target against the reaffirmed positive rating.